#22 Harnessing Divergent Species to Access Difficult and Conserved Antibody Targets (On Demand)

To exploit highly conserved and difficult drug targets, including GPCRs and ion channels, monoclonal antibody discovery efforts are increasingly relying on the advantages offered by divergent species such as rabbits, camelids, and chickens. Divergent host species enable robust immune responses against highly conserved binding sites and yield antibodies capable of penetrating functional pockets via long HCDR3 regions. Pan-reactive molecules are often produced by divergent hosts, and these antibodies can be tested in accessible animal models, offering a faster path to clinical development. In this webinar, Dr. Ross Chambers will analyze gaps in therapeutic antibodies that stem from the historic use of mice and examine opportunities to exploit previously inaccessible targets through discovery in alternate species. Examples of preclinical and clinical-stage antibodies raised in divergent species will be highlighted, providing an overview of their success

Seminar Information
Date Presented:
April 25, 2024 11:00 AM Eastern
Length:
1 hour
Register Now
In order to access this program after registering, a TAS account will be provided for you based on the information you have entered.

To access your account after your purchase, use the My Account links on the left hand side of this page to login using the information your provide here.
According to our records there is already a TAS account using the email address you have provided.

To continue with your registration please enter your account password. If you do not know your account password you can retrieve it here: Forgot Password?
First Name:
Last Name:
Email:
Confirm Email:
Organization:
Country:
Product:
On-Demand
The email address you have entered has an existing TAS account.

Please enter your password in the field below. Forgot Password?

Email:
Password:
Country:
Billing Address:
City:
State:
State/Province:
Zip:
Expiration: 
Harnessing Divergent Species to Access Difficult and Conserved Antibody Targets

To exploit highly conserved and difficult drug targets, including GPCRs and ion channels, monoclonal antibody discovery efforts are increasingly relying on the advantages offered by divergent species such as rabbits, camelids, and chickens. Divergent host species enable robust immune responses against highly conserved binding sites and yield antibodies capable of penetrating functional pockets via long HCDR3 regions. Pan-reactive molecules are often produced by divergent hosts, and these antibodies can be tested in accessible animal models, offering a faster path to clinical development. In this webinar, Dr. Ross Chambers will analyze gaps in therapeutic antibodies that stem from the historic use of mice and examine opportunities to exploit previously inaccessible targets through discovery in alternate species. Examples of preclinical and clinical-stage antibodies raised in divergent species will be highlighted, providing an overview of their success.

Speaker Information
Ross Chambers  [ view bio ]
Individual topic purchase: Selected